menu
    • menu
    [{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"National Cancer Institute | Pinnacle Biologics | Simphotek Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Photofrin Porfimer Sodium","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ National Cancer Institute | Pinnacle Biologics | Simphotek Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ National Cancer Institute | Pinnacle Biologics | Simphotek Inc."},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"Lumeda","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Photofrin Porfimer Sodium","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ Lumeda","highestDevelopmentStatusID":"6","companyTruncated":"Roswell Park Cancer Institute \/ Lumeda"},{"orgOrder":0,"company":"Concordia Labs Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Photofrin Porfimer Sodium","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Concordia Labs Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concordia Labs Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Concordia Labs Inc \/ Undisclosed"},{"orgOrder":0,"company":"Concordia Labs Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Photofrin Porfimer Sodium","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Concordia Labs Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concordia Labs Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Concordia Labs Inc \/ Undisclosed"},{"orgOrder":0,"company":"Concordia Labs Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Photofrin Porfimer Sodium","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Concordia Labs Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concordia Labs Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concordia Labs Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pinnacle Biologics","sponsor":"Harry T Whelan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Photofrin Porfimer Sodium","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Pinnacle Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pinnacle Biologics \/ Harry T Whelan","highestDevelopmentStatusID":"8","companyTruncated":"Pinnacle Biologics \/ Harry T Whelan"},{"orgOrder":0,"company":"Pinnacle Biologics","sponsor":"Harry T Whelan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Photofrin Porfimer Sodium","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Pinnacle Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pinnacle Biologics \/ Harry T Whelan","highestDevelopmentStatusID":"8","companyTruncated":"Pinnacle Biologics \/ Harry T Whelan"},{"orgOrder":0,"company":"Pinnacle Biologics","sponsor":"John DeWitt","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Photofrin Porfimer Sodium","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Pinnacle Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pinnacle Biologics \/ John DeWitt","highestDevelopmentStatusID":"6","companyTruncated":"Pinnacle Biologics \/ John DeWitt"}]

    Find Clinical Drug Pipeline Developments & Deals for PORFIMER SODIUM

    Menu

    PORFIMER SODIUM

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Roswell Park Cancer Institute

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Roswell Park Cancer Institute

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : National Cancer Institute | Pinnacle Biologics | Simphotek Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced L...

                            Details : Porfimer Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lung Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 08, 2018

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : National Cancer Institute | Pinnacle Biologics | Simphotek Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Roswell Park Cancer Institute

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Roswell Park Cancer Institute

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Lumeda

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothel...

                            Details : Porfimer Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Mesothelioma, Malignant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2018

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Lumeda

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Concordia Labs Inc

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Concordia Labs Inc

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety of PDT-Photofrin® Prior to Lung Surgery

                            Details : Porfimer Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lung Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 17, 2017

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Concordia Labs Inc

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Concordia Labs Inc

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral L...

                            Details : Porfimer Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 27, 2016

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Concordia Labs Inc

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Concordia Labs Inc

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

                            Details : Porfimer Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Klatskin Tumor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 10, 2014

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pinnacle Biologics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pinnacle Biologics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Harry T Whelan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

                            Details : Porfimer Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 22, 2013

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Harry T Whelan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pinnacle Biologics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pinnacle Biologics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : John DeWitt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancrea...

                            Details : Porfimer Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Pancreatic Acinar Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 17, 2013

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : John DeWitt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pinnacle Biologics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pinnacle Biologics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Harry T Whelan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

                            Details : Porfimer Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 11, 2012

                            Lead Product(s) : Photofrin Porfimer Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Harry T Whelan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth